Compare Gilead Sciences, Inc. (GILD) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Match Group Inc — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while Match Group Inc trades at $40.84 (market cap $9.36B). The key difference: Gilead Sciences, Inc. is far larger — about 17.5× Match Group Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | MTCH | |
|---|---|---|
Market Cap | $163.51B | $9.36B |
Sector | Health | Media |
52-Week High | $155.80 | $40.11 |
52-Week Low | $108.22 | $28.90 |
Enterprise Value | $178.05B | $12.31B |
Dividend Yield | 2.49% | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
MTCH trades at $40.71, up 6.18% in the last session, with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with a P/E of 15.31, net income margin of 18.83%, and consistent earnings beats in recent quarters. Operating cash flow grew to $1.08B in 2025, while revenue remains stable at $3.49B. Recent news highlights Tinder's turnaround efforts and Hinge's growth, with Q2 2026 earnings due August 4, 2026.
The outlook is positive with a consensus price target of $41.63, implying modest upside. Risks include high long-term debt of $3.85B and declining Tinder users, offset by pricing power and AI features. Institutional sentiment is bullish with no sell ratings, but investors should monitor Q2 earnings for growth sustainability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
